Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

INSIST · IN-Silico trials for treatment of acute Ischemic STroke

H2020Status: CLOSED1 November 201730 April 2022EU funding €5,250,675Call H2020-SC1-2016-2017

Stroke is the number one cause of disability in the Western world and the 3rd most common cause of death. Despite new treatment options with intra-arterial thrombectomy, still 2 out of 3 patients still have a poor outcome. The main goal of INSIST is to advance treatments of ischemic stroke and its introduction in clinical practice by realizing in silico clinical stroke trials in which stroke and treatment are modeled. We will generate virtual populations of stroke patients, generate and validate in silico models for intra-arterial thrombectomy, thrombosis and thrombolysis, and microvascular perfusion and neurological deterioration after stroke, and integrate the in silico models to realize an in silico clinical stroke trial. We are uniquely positioned by the availability of a large pool of clinical, imaging, histopathological, and outcome data from multiple recently finalized stroke trials, a large registry (totaling 4500 patients), and new trials that will start later this year (totaling 2500 patients). We will build a population model that takes this input to generate virtual populations of stroke patients addressing the wide variety of patient characteristics. We will build on existing and emerging in silico models to validate reusable models for stroke and stroke treatment with a strong interaction with experimenting modeling in laboratories. The in silico models and virtual populations will be combined to simulate clinical trials and validated by simulating and comparing finalized and currently running trials. The in silico models will be used to simulate clinical trials to evaluate effectiveness and safety of novel devices and medication, both for the device as well as the pharmacological industry. For the device industry, we will evaluate the optimal configuration of thrombectomy stents for reduction of thrombus fragmentation. From the perspective of the pharmacy industry, we will simulate the effect of increased TAFIa on the effectiveness of alteplase.

Consortium · 11 organisations

coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

NL · €908,085

participant

UNIVERSITY OF GALWAY

IE · €425,365

participant

UNIVERSITE DE GENEVE

CH · €771,975

participant

NEURAVI LIMITED

IE · €416,275

participant

POLITECNICO DI MILANO

IT · €349,600

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €568,125

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €717,500

participant

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

FR · €85,500

participant

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €462,500

participant

M.V. LOMONOSOV MOSCOW STATE UNIVERSITY

RU

participant

UNIVERSITEIT VAN AMSTERDAM

NL · €545,750

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.